NYSE:TARO Taro Pharmaceutical Industries - TARO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Taro Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $25.03 +0.03 (+0.12%) (As of 03/23/2023 12:04 PM ET) Add Compare Share Share Today's Range$25.00▼$25.3250-Day Range$25.00▼$31.5952-Week Range$24.98▼$45.62Volume3,507 shsAverage Volume12,198 shsMarket Capitalization$940.63 millionP/E Ratio20.52Dividend YieldN/APrice Target$35.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Taro Pharmaceutical Industries MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside40.0% Upside$35.00 Price TargetShort InterestBearish0.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector386th out of 986 stocksPharmaceutical Preparations Industry176th out of 477 stocks 3.5 Analyst's Opinion Consensus RatingTaro Pharmaceutical Industries has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.00, Taro Pharmaceutical Industries has a forecasted upside of 40.0% from its current price of $25.00.Amount of Analyst CoverageTaro Pharmaceutical Industries has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.72% of the float of Taro Pharmaceutical Industries has been sold short.Short Interest Ratio / Days to CoverTaro Pharmaceutical Industries has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Taro Pharmaceutical Industries has recently increased by 2.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTaro Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTaro Pharmaceutical Industries does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TARO. Previous Next 3.1 News and Social Media Coverage News SentimentTaro Pharmaceutical Industries has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Taro Pharmaceutical Industries this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Taro Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Taro Pharmaceutical Industries insiders have not sold or bought any company stock.Percentage Held by Insiders13.80% of the stock of Taro Pharmaceutical Industries is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.45% of the stock of Taro Pharmaceutical Industries is held by institutions. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Taro Pharmaceutical Industries is 20.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 124.22.Price to Earnings Ratio vs. SectorThe P/E ratio of Taro Pharmaceutical Industries is 20.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 97.32.Price to Book Value per Share RatioTaro Pharmaceutical Industries has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Taro Pharmaceutical Industries (NYSE:TARO) StockTaro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.Read More Receive TARO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Email Address TARO Stock News HeadlinesMarch 22, 2023 | marketwatch.com2023-2028 Nonvalvular Atrial Fibrillation Drugs Market Predictions and Growth Opportunities | Latest Research ReportMarch 21, 2023 | uk.finance.yahoo.comTopical Drug Delivery Global Market Report 2023March 23, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 21, 2023 | marketwatch.comTopical Antibiotics Market Growth and Forecast till 2028March 16, 2023 | marketwatch.comTinea Versicolor Treatment Market Growth and Forecast till 2028March 16, 2023 | americanbankingnews.comTaro Pharmaceutical Industries (NYSE:TARO) Now Covered by Analysts at StockNews.comMarch 14, 2023 | seekingalpha.comTARO Taro Pharmaceutical Industries Ltd.March 14, 2023 | marketwatch.comEnalapril Market Size, Growth Rate, Key Players Share, Trends Analysis with Forecast 2023-2028March 23, 2023 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. March 13, 2023 | marketwatch.comPseudotumor Cerebri Market Application, Product, Sales and Forecast 2023-2028March 8, 2023 | marketwatch.com2023-2029 Pseudotumor Cerebri Market Size and Porters Five Forces Analysis | Survey Report by Absolute ReportsMarch 8, 2023 | marketwatch.comKetoconazole Market Size Global Research Report, 2023 - 2028February 28, 2023 | marketwatch.comActinic Keratosis Drugs Market Size, Share & Trends Analysis Forecast Report by 2028February 26, 2023 | marketwatch.comActinic Keratosis Market Report with Executive Summary, Size, Analysis and Forecast to 2023-2028February 25, 2023 | marketwatch.comUrticaria Drug Market Outlook 2023 and Forecast to 2028 with Top Countries DataFebruary 25, 2023 | seekingalpha.comTaro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate HoldFebruary 25, 2023 | marketwatch.comAn Overview of Pseudotumor Cerebri Market, Major Participants, and Prospects by 2028February 25, 2023 | marketwatch.comGlucose Analysis Tubes Market Size (Release 2023): SWOT Analysis by Competitors and Forecast till 2029February 21, 2023 | marketwatch.comNystatin and Triamcinolone Acetonide Market Size, Share and Forecast 2028 with Top Countries DataFebruary 14, 2023 | marketwatch.comWarfarin Market In-depth analysis which provides critical revenue and estimates for the period 2023 To 2028February 13, 2023 | marketwatch.comAnalysis of the Clotrimazole and Betamethasone Diproprionate Market 2023-2028: Trends and Spending BehavioursFebruary 10, 2023 | marketwatch.comGranisetron Market Research 2023 : Growth, Trends, Outlook and Future Scope Analysis 2028February 9, 2023 | marketwatch.comMupirocin Market 2023 Industry Size, Share, Trends, Opportunities, Growth Analysis and Forecast to 2028February 8, 2023 | marketwatch.comKetoconazole Market Demand, Share, Key Players, Size, Growth Analysis, and Forecast 2028February 1, 2023 | marketwatch.comLetrozole Market 2023 : Top Countries Data with Growth Rate Competitive Landscape and Forecast To 2028January 27, 2023 | finance.yahoo.comTaro Pharmaceutical Industries Third Quarter 2023 Earnings: Misses ExpectationsJanuary 27, 2023 | marketwatch.comIron Chelation Drug Market Size, Outlook, Share, Prominent Players, Growth, and Forecast 2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TARO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Email Address TARO Company Calendar Last Earnings1/24/2023Today3/23/2023Fiscal Year End3/31/2023Next Earnings (Estimated)5/25/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:TARO CUSIPN/A CIK906338 Webwww.taro.com Phone(724) 847-5700Fax914-345-6169Employees1,455Year FoundedN/APrice Target and Rating Average Stock Price Forecast$35.00 High Stock Price Forecast$35.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+40.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$1.22 Trailing P/E Ratio20.49 Forward P/E Ratio34.72 P/E GrowthN/ANet Income$58.27 million Net Margins8.06% Pretax Margin7.96% Return on Equity2.68% Return on Assets2.16% Debt Debt-to-Equity RatioN/A Current Ratio3.72 Quick Ratio3.12 Sales & Book Value Annual Sales$569.41 million Price / Sales1.65 Cash Flow$3.90 per share Price / Cash Flow6.41 Book Value$45.54 per share Price / Book0.55Miscellaneous Outstanding Shares37,585,000Free Float32,398,000Market Cap$939.63 million OptionableOptionable Beta0.66 Key ExecutivesUday Vijaykumar BaldotaChief Executive Officer & DirectorWilliam J. CooteChief Financial, VP & Accounting OfficerHagai ReingoldVice President & Head-OperationsItamar KarsentiVice President & Head-OperationsAvi AvramoffVice President & Head-Research & DevelopmentKey CompetitorsCassava SciencesNASDAQ:SAVABELLUS HealthNASDAQ:BLU23andMeNASDAQ:MERhythm PharmaceuticalsNASDAQ:RYTMOPKO HealthNASDAQ:OPKView All CompetitorsInstitutional OwnershipEversept Partners LPBought 2,079 shares on 2/15/2023Ownership: 0.600%Norges BankBought 60,790 shares on 2/15/2023Ownership: 0.162%Morgan StanleySold 11,573 shares on 2/15/2023Ownership: 0.118%Stokes Family Office LLCBought 10,600 shares on 2/15/2023Ownership: 0.028%Legal & General Group PlcBought 339 shares on 2/15/2023Ownership: 0.018%View All Institutional Transactions TARO Stock - Frequently Asked Questions Should I buy or sell Taro Pharmaceutical Industries stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TARO shares. View TARO analyst ratings or view top-rated stocks. What is Taro Pharmaceutical Industries' stock price forecast for 2023? 1 equities research analysts have issued 1 year price objectives for Taro Pharmaceutical Industries' shares. Their TARO share price forecasts range from $35.00 to $35.00. On average, they anticipate the company's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 40.0% from the stock's current price. View analysts price targets for TARO or view top-rated stocks among Wall Street analysts. How have TARO shares performed in 2023? Taro Pharmaceutical Industries' stock was trading at $29.04 on January 1st, 2023. Since then, TARO shares have decreased by 13.9% and is now trading at $25.00. View the best growth stocks for 2023 here. When is Taro Pharmaceutical Industries' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 25th 2023. View our TARO earnings forecast. How were Taro Pharmaceutical Industries' earnings last quarter? Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its earnings results on Tuesday, January, 24th. The company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.87 by $0.68. The firm earned $139.20 million during the quarter, compared to analysts' expectations of $163.12 million. Taro Pharmaceutical Industries had a net margin of 8.06% and a trailing twelve-month return on equity of 2.68%. What ETFs hold Taro Pharmaceutical Industries' stock? ETFs with the largest weight of Taro Pharmaceutical Industries (NYSE:TARO) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL) and iShares MSCI Israel ETF (EIS).VanEck Israel ETF (ISRA). What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO? 11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Taro Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV). What is Taro Pharmaceutical Industries' stock symbol? Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO." Who are Taro Pharmaceutical Industries' major shareholders? Taro Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.63%), Dimensional Fund Advisors LP (1.52%), Eversept Partners LP (0.60%), Murchinson Ltd. (0.28%), Cowen AND Company LLC (0.19%) and ARK Investment Management LLC (0.18%). How do I buy shares of Taro Pharmaceutical Industries? Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Taro Pharmaceutical Industries' stock price today? One share of TARO stock can currently be purchased for approximately $25.00. How much money does Taro Pharmaceutical Industries make? Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $939.63 million and generates $569.41 million in revenue each year. The company earns $58.27 million in net income (profit) each year or $1.22 on an earnings per share basis. How many employees does Taro Pharmaceutical Industries have? The company employs 1,455 workers across the globe. How can I contact Taro Pharmaceutical Industries? Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for the company is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169. This page (NYSE:TARO) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.